ArticleThe Pan African medical journal2025
[Abdominal tuberculosis: a 13-year experience].
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal tuberculosis (ATB) is a rare but serious form of extrapulmonary tuberculosis. We conducted a prospective descriptive study including all patients hospitalized for abdominal tuberculosis at Mahres Regional Hospital between January 2012 and December 2024. Fourteen patients were included. Risk factors included a personal history of tuberculosis (28.5%), family history (21.4%), diabetes mellitus (21.4%), consumption of unpasteurized milk (28.5%), and contact with animals (21.4%). The main sites of involvement were peritoneal (42.8%) and intestinal (42.8%), with mesenteric lymph node involvement observed in 21.4% of cases. Extra-abdominal tuberculosis was present in 35.7% of patients. The diagnosis was based on microbiological methods (42.8%), histological findings (35.7%), and/or clinical features (21.4%). All patients received multi-drug anti-tuberculosis therapy for a median duration of 11 months, which was well tolerated except in 14.2% of cases. Abdominal tuberculosis remains a rare entity with diverse and often misleading clinical presentations, underscoring the importance of early clinical suspicion and multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.